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ABSTRACT
Patients with hormone-resistant prostate cancer (PCa) have higher biochemical 
failure rates following radiation therapy (RT). Cyclin D1 deregulated expression in PCa 
is associated with a more aggressive disease: however its role in radioresistance has 
not been determined. Cyclin D1 levels in the androgen-independent PC3 and 22Rv1 
PCa cells were stably inhibited by infecting with cyclin D1-shRNA. Tumorigenicity 
and radiosensitivity were investigated using in vitro and in vivo experimental assays. 
Cyclin D1 silencing interfered with PCa oncogenic phenotype by inducing growth 
arrest in the G1 phase of cell cycle and reducing soft agar colony formation, migration, 
invasion in vitro and tumor formation and neo-angiogenesis in vivo. Depletion of cyclin 
D1 significantly radiosensitizes PCa cells by increasing the RT-induced DNA damages 
by affecting the NHEJ and HR pathways responsible of the DNA double-strand break 
repair. Following treatment of cells with RT the abundance of a biomarker of DNA 
damage, γ-H2AX, was dramatically increased in sh-cyclin D1 treated cells compared to 
shRNA control. Concordant with these observations DNA-PKcs-activation and RAD51-
accumulation, part of the DNA double-strand break repair machinery, were reduced 
in shRNA-cyclin D1 treated cells compared to shRNA control. We further demonstrate 
the physical interaction between CCND1 with activated-ATM, -DNA-PKcs and RAD51 is 
enhanced by RT. Finally, siRNA-mediated silencing experiments indicated DNA-PKcs 
and RAD51 are downstream targets of CCND1-mediated PCa cells radioresistance. 
In summary, these observations suggest that CCND1 is a key mediator of PCa 
radioresistance and could represent a potential target for radioresistant hormone-
resistant PCa.
INTRODUCTION
Prostate cancer (PCa) is the most commonly 
diagnosed male malignancy and the second leading 
cause of cancer death in men. Radiation therapy (RT), 
considered as a major therapeutic modality for PCa 
treatment, is a non-invasive outpatient therapy that can 
be used alone, as adjuvant to surgery and/or combined 
with androgen deprivation therapy [1]. Although, RT 
generally results in an excellent initial response, some 
patients relapse locally and/or systemically, indicating 
that a resistant population of cancer cells may have 
survived the RT [1–2]. Clinical observation shows that 
patients with androgen-independent PCa appear to 
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have higher biochemical failure rates after RT. Previous 
studies also indicate that the response to RT is different 
between androgen-dependent and androgen-independent 
PCa cells, indicating that molecular events mediated by 
androgen may also function in radiosensitization and that 
androgen-independency may be associated with radiation 
resistance in PCa [3]. Although various genetic, epigenetic 
and molecular abnormalities have been associated with 
radiation resistance in PCa [4], the molecular mechanisms 
responsible of radiation resistance and relationship 
with androgen-independent PCa phenotype remains 
unknown. Understanding these phenomena could lead to 
new molecular targets and more directed therapy able to 
improve the RT efficiency.
RT promotes cytotoxicity by inducing several forms 
of DNA damage such as double-strand breaks (DSBs). 
Two mechanisms exist to repair mammalian DSBs: 
non-homologous end joining (NHEJ) and homologous 
recombination (HR) that are chosen depending in part 
upon the phase of the cell cycle and chromatin context 
[5]. It is generally considered that accurate repair by 
HR is restricted to S and G2 phases of the cell cycle, 
whereas NHEJ is predominant in G0/G1 cells [5–6]. 
Ataxia telangiectasia mutated (ATM) and the DNA 
dependent protein kinase catalytic subunit (DNA-PKcs) 
play a key roles in the DSBs response, via HR and NHEJ, 
respectively. Once activated, ATM and DNA-PKcs regulate 
a wide spectrum of downstream targets that are involved 
in the DNA damage repair process, cell cycle regulation 
and apoptosis [7]. Tumor cells escape from RT induced 
cytotoxicity by activating a complex network of pathways 
able to remove DSBs and to permit cell cycle progression 
[5]. Furthermore, RT can also simultaneously induce 
multiple pro-survival signaling pathways which can lead 
to suppression of apoptosis, induction of cell cycle arrest 
and/or initiation of DNA repair. These signaling pathways 
act in concert to reduce the magnitude of radiation-
induced cytotoxicity and promote the development of 
radioresistance in cancer cells [8–9]. The identification of 
the molecular mechanisms involved in the DNA damage 
response raises the possibility to specifically target cancer 
cells inducing a radiosensitization [10–11].
The D-type cyclin family, composed of three 
proteins, Cyclin D1, D2 and D3, regulates the G1/S-
phase transition of proliferating cells [12]. Of the three 
D-type cyclins, it is cyclin D1 overexpression that is 
predominantly associated with human tumorigenesis 
and cellular metastases. Amplification or overexpression 
of cyclin D1 plays pivotal roles in the development of a 
subset of human cancers including parathyroid adenoma, 
breast cancer, colon cancer, lymphoma, melanoma, and 
prostate cancer [13–16]. Increasing evidences show 
that cyclin D1 governs DNA damage repair through 
forming and regulating several multi-protein DNA 
repair complexes that participate in DNA repair [17–22]. 
Despite the evidence collected implicating cyclin D1 
in DNA repair and radioresistance of cancer cells, little 
is known about its role in prostate cancer cells and the 
relationship between cyclin D1, androgen independency 
and radioresistance.
In this manuscript, we investigated whether 
silencing cyclin D1 affects the radiosensitivity of 
androgen-independent, androgen-receptor negative PC3 
[23–24] and androgen-independent, androgen-receptor 
positive 22Rv1 cells [25] by deploying in vitro and 
in vivo models systems. We generated stably infected cell 
lines expressing shRNA against cyclin D1. Herein, cyclin 
D1 depletion suppressed the tumorigenic phenotype and 
increased the radiosensitivity of PCa cell lines both in vitro 
and in vivo. Cyclin D1 silencing impaired the DSBs repair 
mediated by the NHEJ and HR molecular machinery. 
These results substantiate the idea that cyclin D1 is an 
important regulator of tumorigenesis and radioresistance 
of androgen-independent PCa cells. 
RESULTS
Silencing cyclin D1 affects the cell lines PC3 and 
22Rv1 oncophenotype
An shRNA sequence versus cyclin D1, cloned in the 
GFP-expressing pLVTHM plasmid, was used to knock 
down expression of cyclin D1 in the PC3 (Figure 1) and 
22Rv1 (Figure 2) PCa cell lines. As extensively described 
in the Material and Methods section, GFP-positive cells, 
isolated by FACS sorting for GFP+ cells, were expanded 
and examined by western blot for the cyclin D1 protein 
abundance. PC3- (Figure 1A) and 22Rv1- (Figure 2A) 
shRNA-cyclin D1 infected cells showed a significant 
reduction in cyclin D1 protein expression (Figures 1A 
PC3 and 2A 22Rv1). We conducted experiments that 
compared tumorigenicity of the shRNA-cyclin D1- 
versus shRNA-control-transduced cells. Delay in cell 
growth, cell cycle analysis, soft agar colony formation-, 
migration- and invasion-abilities were investigated. 
Silencing cyclin D1 leds to a delay in growth of PCa 
cells: PC3- and 22Rv1-Cyclin D1-shRNA transduced 
cells respectively demonstrated a 5-fold decrease at 
10-days and a 2-fold decrease at 12 days in proliferation 
compared to control-shRNA transduced cells (Figures 2B 
and 3B). FACS analysis shows that silencing cyclin D1 
increased the proportion of PC3 (Figure 1C) and 22Rv1 
(Figure 2C) cells in G1 phase and up-regulated the p21
Waf1 
and p27Kip2 cell cycle inhibitor protein expression levels. 
Figure 1D (PC3) and 2D (22Rv1) show that silencing 
cyclin D1 reduced by 80% (PC3) and 82.5% (22Rv1) the 
ability to form colony in soft agar and by 69% (PC3) and 
48% (22Rv1) the colony medium size. Figure 1E (PC3) 
and 2E (22Rv1) show that cyclin D1 silencing reduced 
by 83% (PC3) and 77% (22Rv1) invasion and by 68% 
(PC3) and 71% (22Rv1) migration abilities. Given the 
observed effects on invasion and migration, the matrix 
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metallopeptidase 2 and 9 (MMP-2 and -9) activities were 
assessed by ELISA assay. Figures 1F and 2F show that 
cyclin D1 depletion reduced the MMP-2 activity by 81% 
(PC3) and 82% (22Rv1), the MMP-9 activity by 65% 
(PC3) and 62% (22Rv1).
Cyclin D1 governs the radioresistant phenotype 
of PC3 and 22Rv1 cell lines in vitro and in vivo
We investigated the effect of silencing cyclin D1 
combined with radiotherapy of human PCa cell lines 
in vitro and in vivo. For the in vitro experiments, control- 
and cyclin D1-shRNA transduced cells were treated with 
several doses (0–8 Gy) of radiation. MTT assay (Figure 3A), 
performed after 24 hrs post irradiation, shows that silencing 
cyclin D1 significantly reduced the PC3 and 22Rv1 
cells survival. Colony formation assay was performed 
to determine cell reproductive death after treatment 
with ionizing radiation. Concordant with the delay in 
growth intrinsic to cyclin D1-shRNA transduced cells, 
colonies from control-shRNA transduced cells could be 
counted after 14 days while those from cyclin D1-shRNA 
transduced cells could not be evaluated until 45 days post 
irradiation. As shown in Figure 3B, a significant reduction 
Figure 1: Stable and Specific Silencing of cyclin D1 inhibits PC3 onco-phenotype. (A) Parental PC3 (PRT), GFP-positive 
PC3 cells, stably infected with shRNA-cyclin D1 (CD1) vs. shRNA-control (CTR) sequence (CTR), were selected by FACS sorting and 
examined for cyclin D1 protein expression by immunoblotting. (B) Cell growth assay, (C) cell cycle distribution by FACS and p21waf1, 
p27KIP2 by immunoblotting, (D) soft agar assay and relative colony size, (E) invasion- and migration-assay and (F) the activation status of 
MMP-2 and MMP-9 by ELISA assay were performed. The data presented in Figure 1B, 1C, 1D, 1E and 1F represent the mean ± SD of 3 
independent experiments. Statistical analysis was performed using the Student’s t-test, P < 0.01. For immunoblotting, α-tubulin expression 
shows equal loading. Similar results were obtained in n = 3 experiments.
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in number of cell colonies were observed in cyclin D1-
shRNA + RT groups compared to control-shRNA group at 
all tested doses of radiation in both cell lines. For in vivo 
experiments, RT treatment (5 fractions of 2 Gy delivered 
over 5 consecutive days for a total dose of 10 Gy) was 
started when tumor volume reached 0.5–1.0 mm3 (T0). 
Tumor volumes were measured every 4 days for a period 
of 24 days (Figure 4A) while tumor weight was measured 
at the end of the experiment (Figure 4B). PC3- and 22Rv1-
cyclin D1-shRNA xenografted mice grew significantly less 
Figure 2: Stable and Specific Silencing of cyclin D1 inhibits 22Rv1 onco-phenotype. (A) Parental 22Rv1 (PRT), GFP-positive 
22Rv1 cells, stably infected with shRNA-cyclin D1 (CD1) vs. shRNA-control (CTR) sequence (CTR), were selected by FACS sorting and 
examined for cyclin D1 protein expression by immunoblotting. (B) Cell growth assay, (C) cell cycle distribution by FACS and p21waf1, 
p27KIP2 by immunoblotting, (D) soft agar assay and relative colony size, (E) invasion- and migration-assay and (F) the activation status of 
MMP-2 and MMP-9 by ELISA assay were performed. The data presented in Figure 1B, 1C, 1D, 1E and 1F represent the mean ± SD of 3 
independent experiments. Statistical analysis was performed using the Student’s t-test, P < 0.01. For immunoblotting, α-tubulin expression 
shows equal loading. Similar results were obtained in n = 3 experiments.
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with respect to control groups and RT treatment decreased 
growth further (Figure 4A). These effects were confirmed 
by measuring tumor weight (Figure 4B). The number of 
mice with tumor progression significantly differed across 
the groups and this was confirmed by the mean values 
of TTP (Figure 4C). In the mice xenografted with tumor 
cells expressing cyclin D1-shRNA, tumor progressions 
occurred within 12 and 14 days after the T0 in PC3 and 
22Rv1 tumor cells, respectively (Figure 4C). The mean 
TTP of these xenografts was of 11.6 days (95% CI 11.3 
to 11.9) in PC3 and 13.4. days (95% CI 13.1 to 13.7) in 
22Rv1, respectively. Although an effect of RT, in terms of 
tumor weight and tumor volume, was observed in 22Rv1 
expressing cyclin D1, a negligible improvement in the TTP 
was documented in this xenograft model [13.0. days (95% 
CI 12.9 to 13.8)] with respect to controls. In contrast PC3 
cells expressing cyclin D1 [15.2. days (95% CI 14.7 to 
15.7)] demonstrated, an improvement of the RT response 
compared to controls. Interestingly, when cyclin D1 was 
silenced the TTP was significantly prolonged (p < 0.05) 
Figure 3: Silencing cyclin D1 radiosensitizes PC3 and 22Rv1 cell lines in vitro. shRNA-cyclin D1- (CD1) and shRNA-control-
transduced (CTR) PC3 and 22Rv1 cells were irradiated with various doses (0–8 Gy): (A) MTT and (B) (Upper Panel) colony formation 
assays were performed. The data presented in Figure 3A and 3B Upper Panel represent the mean ± SD of 3 independent experiments. 
Statistical analysis was performed using the Student’s t-test, P < 0.01. Figure 3B Lower Panel shows the effects of 4 Gy irradiation on 
shRNA-cyclin D1- and shRNA-control-transduced PC3 and 22Rv1 cells. 
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with respect to controls and RT resulted in no tumor 
progression in both xenograft models (Figure 4C). Masson 
trichromic staining was performed to evaluate collagen 
deposition and changes in the prostatic parenchymal 
architecture (Figure 5, Masson Trichromic). Tumor 
masses from control-shRNA transduced cells showed the 
presence of nodules surrounded by bundles of connective 
tissue together with a massive neovascularization close 
to the nodules and throughout the entire parenchyma; RT 
treatment did not induce any substantial modification. 
Silencing cyclin D1 induced a marked changes in the 
morphological pattern with an almost normal parenchymal 
architecture, a normal collagen distribution; these effects 
were enhanced by RT treatment. Collagen density was 
also evaluated by colorimetric assay (Figure 5, % Control 
Collagen Density). Silencing cyclin D1 per se decreased 
collagen density by 48.2% (PC3) and 59.1% (22Rv1): 
these effects were potentiated by RT treatment resulting in 
a further decrease of the collagen density by 78.3% (PC3) 
and 85.3% (22Rv1). RT did not modify collagen density 
Figure 4: Silencing cyclin D1 radiosensitizersPC3 and 22Rv1 cell lines in vivo. Mice xenografted with shRNA-cyclin D1- 
(CD1) and shRNA-control-transduced (CTR) PC3 (Left Panel) or 22Rv1 (Right Panel) cells subjected to radiation treatment (5 fractions 
of 2 Gy were delivered over 5 consecutive days for a total dose of 10 Gy) starting when the tumor volume reached 0.5–1.0 mm3 (T0). 
(A) Tumor volume, (B) tumor weights and (C) number of mice with tumor progression.
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of control-shRNA transduced cells. Vascular response to 
silencing cyclin D1 was analyzed by α-SMA staining and 
protein expression quantification (Figure 5, α-SMA). There 
was significant difference in α-SMA protein expression. 
Compared to control-shRNA-transduced group, in 
cyclin D1-shRNA transduced group the α-SMA protein 
expression was reduced by 61.5% (PC3) and 47.2% 
(22Rv1). These effects were enhanced by RT treatment 
resulting in a further α-SMA protein expression reduction 
by 94.2% (PC3) and 81.3% (22Rv1). Figure 5A and 5B 
(cyclin D1) depicts the immunohistochemical analysis and 
protein expression quantification for cyclin D1.
Silencing cyclin D1 radiosensitizes PCa cells by 
impairing the NHEJ-DNA-PKcs and 
HR-ATM-RAD51 pathways responsible  
for the DNA double-strand break repair
We assessed whether silencing cyclin D1 may 
sensitize PCa cells to ionizing radiation by inducing 
apoptosis and/or promoting the DNA damage and 
impairing the molecular mechanisms of DSBs repair. To 
this purpose, control- and cyclin D1-shRNA transduced 
cells were irradiated with a single dose of 4 Gy and cell 
lysates were processed 6 hours after RT. The analysis 
Figure 5: Immunohistochemistry, α-SMA and cyclin D1 staining in sections from mice xenografted with PC3 and 22Rv1 
cell lines and subjected to radiotherapy. Mice xenografted with shRNA-cyclin D1- (CD1) and shRNA-control-transduced (CTR) 
PC3 (Upper Panel) or 22Rv1 (Lower Panel) cells subjected to radiation treatment (5 fractions of 2 Gy were delivered over 5 consecutive 
days for a total dose of 10 Gy) starting when the tumor volume reached 0.5–1.0 mm3. Masson’s thrichromic staining, α-SMA and cyclin D1 
staining. Original Magnification 10X. Insert: original magnification 40X. (A and B Right Panel) Protein quantification. The data presented 
represent the mean ± SD of 3 independent experiments. Statistical analysis was performed using the Student’s t-test, P < 0.01.
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of apoptotic markers show that 4 Gy RT treatment did 
not induce significant apoptosis of cyclin D1- versus 
control-shRNA transduced cells (Data not shown).
We next tested the abundance of γ-H2AX levels, a 
biomarker for DNA double-strand breaks, as well as the 
activation status and/or abundance of ATM, DNA-PKcs, 
RAD51 and RAD86 that govern the DNA-DSBs repair 
machinery. ELISA (Figure 6A) and western blot (Figure 
6B, γ-H2AX) showed that in the presence of silencing 
cyclin D1, RT significantly increased the DNA damage 
as suggested by the upregulation of γ-H2AX protein 
expression levels. Cyclin D1 depletion counteracted 
DNA-PKcsThr2609 phosphorylation/activation and the 
accumulation of RAD51 and Ku86 proteins induced 
by RT. No effects on ATMSer1981 phosphorylation status 
was observed (Figure 6B). The ability of cyclin D1 to 
directly interact with the proteins of DNA-DSBs repair 
machinery was investigated. PC3 and 22Rv1 cells 
were irradiated with a single dose of 4 Gy and, after 6 
hours, cell lysates were immunoprecipitated for cyclin 
Data not shown. Cyclin D1 silencing did not radiosensitize by inducing apoptosis. control- (CTR) and cyclin D1-shRNA (CD1) 
transduced PC3 and 22Rv1 cells were subjected to 4 Gy of irradiation. (A) TUNEL assay and the evaluation of caspase-3, -8 and -9 
activation by ELISA (B) and western blott (C) assays were performed after 6 hours from irradiation. The data presented in A and B represent 
the mean ± SD of 3 independent experiments. Statistical analysis was performed using the Student’s t-test, P < 0.01. 
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D1: PKcsThr2609, -ATMSer1981 and RAD51 association 
was tested by immublotting. Cyclin D1 bound DNA-
PKcsThr2609, -ATMSer1981 and RAD51 and the amount of 
activated-DNA/PK,-ATM and RAD51 was significantly 
increased by RT treatment (Figure 6C). The relationship 
between cyclin D1 and DNA-DSBs repair machinery was 
also tested in in vivo experiment on mice xenografted with 
control- or cyclin D1-shRNA transduced PC3 or 22Rv1 
cells, treated or not with RT as already described and 
sacrificed 24 hours after the last RT dose (Figure 7). Also 
in in vivo, silencing cyclin D1 favored the DNA-DSBs 
damage, impairing the DNA-damaged repair. In presence 
of cyclin D1 silencing, RT increased γ-H2AX expression 
by 281% (PC3) and 246% (22Rv1) (Figure 7 γ-H2AX) 
while poor DNA-PKcs activation (DNA-PKcsThr2609), 
Ku86 and RAD51 protein expression (Figure 7) were 
identified. Lastly we investigated if DNA-PKcs- and/
or ATM-RAD51-pathways were downstream targets of 
cyclin D1-mediated radioresistance. To this end, PC3 and 
22Rv1 cells subjected to DNA-PKcs or RAD51 protein 
silencing with specific siRNA, were irradiated with a 
single dose of 4 Gy: γ-H2AX levels were tested by ELISA 
Figure 6: cyclin D1 depletion do not radiosentize via inducing apopotosis but rather by impairing the molecular 
machinery responsible of the DNA double-strand break repair. shRNA-cyclin D1- (CD1) and shRNA-control-transduced (CTR) 
PC3 or 22Rv1 cells irradiated with a single dose of 4 Gy. (A) 6 hours post RT, H2AX activation status was investigated using and ELISA 
assay for γ-H2AX; the data represent the mean ± SD of 3 independent experiments. Statistical analysis was performed using the Student’s 
t-test, P < 0.01. (B) Cell lysate were processed for the indicated proteins by immunoblotting; α-tubulin demonstrates equal loading. Similar 
results were obtained in n = 3 experiments. (C) Cyclin D1-DNA-PKCs, -ATM, -RAD51 heterodimers in PC3 (Upper Panel) or 22Rv1 
(Lower Panel) cells untreated (−) or treated (+) with RT (4 Gy). 6 hours post RT, cyclin D1 was immunoprecipitated (IP) with an anti-cyclin 
D1 polyclonal antibody from extracts containing equal amounts of total proteins and subsequently analyzed by immunoblotting with a 
cyclin D1, DNA-PKCsThr2809, ATMSer1981 or RAD51 monoclonal antibodies. Similar results were obtained in n = 2 experiments.
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Figure 7: Cyclin D1staining in sections from mice xenografted with PC3 and 22Rv1 cell lines and subjected to 
radiotherapy. Mice xenografted with shRNA-cyclin D1- (CD1) and shRNA-control-transduced (CTR) PC3 (Upper Panel) or 22Rv1 
(Lower Panel) cells subjected to radiation treatment (5 fractions of 2 Gy were delivered over 5 consecutive days for a total dose of 10 Gy) 
starting when the tumor volume reached 0.5–1.0 mm3: γ-H2AX, Pospho-DNA-PKCs, Ku86 and RAD51 staining and protein quantification. 
The data represent the mean ± SD of 3 independent experiments. Statistical analysis was performed using the Student’s t-test, P < 0.01.
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at different time post RT treatment. siRNA transfection 
resulted in a downregulation of DNA-PKcs or RAD51 
expression with respect to the siRNA-control-transfected 
cells (Figure 8A). ELISA (Figure 8B) show that DNA-
PKcs or RAD51 silencing significantly favored the DNA 
damage induced by RT. Contrary to siRNA-control-
transfected cells, in which the γ-H2AX upregulation was 
transient and disappeared within 12 hours, DNA-PKcs 
or RAD51 silencing favored a greater and more lasting 
effect on DNA damage, suggesting DNA-PKcs- and ATM/
RAD51-pathway are downstream targets of cyclin D1 
induced PCa cell radioresistance.
DISCUSSION
Radiation therapy (RT) is considered the first line 
treatment for prostate cancer (PCa). Despite technical 
improvements, many patients relapse locally and/or 
with systemic disease, indicating the presence of a radio 
resistant cancer cell population [1–2]. Furthermore, 
several evidence show that PCa cells with an androgen-
independent phenotype have higher biochemical failure 
rates after RT suggesting that androgen-independency 
may be associated with radiation resistance in PCa [3]. 
Cancer cells are frequently characterize by an elevated 
Figure 8: Effects of RAD51 or DNA-PKcs siRNA on DNA damage. (A) Reduced RAD51 or DNA-PKcs expression by 
RAD51 or DNA/PKcs siRNA. Western blot analysis performed using lysates isolated from PC3 (Left Panel) or 22Rv1 (Right Panel) cells 
expressing RAD51, DNA-PKcs or Control siRNA and subjected to 4 Gy of RT. Cell lysates were processed for the indicated proteins by 
immunoblotting; α-tubulin expression shows equal loading. (B) H2AX activation status was investigated by using an ELISA assay for 
γ-H2AX at different time from RT treatment; the data represent the mean ± SD of 3 independent experiments. Statistical analysis was 
performed using the Student’s t-test, P < 0.01. Similar results were obtained in n = 3 experiments.
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DNA repair capacity that leads to radiation resistance 
and targeting the DNA repair machinery could enhance 
the efficacy of RT [10–11]. In previous studies Ccnd1 
gene deletion was associated with reduced proliferation 
of prostate epithelial cells and induction of a cyclin D1 
mediated gene signature that predicted poor outcome 
and recurrence free survival in prostate cancer patients 
[16]. Herein, we investigated if cyclin D1 contributes to 
androgen-independent PCa cells radioresistance. The role 
of cyclin D1 in androgen-independent PCa cells response 
to RT was previously unknown. By using androgen-
independent, androgen-receptor negative PC3 [23–24] 
and androgen-receptor positive 22Rv1 [25] PCa cell lines 
stable infected with shRNA for cyclin D1, we show that 
cyclin D1 is a key regulator in controlling the DNA double 
strand break (DSB) repair mechanisms mediated by the 
non homologous end joining (NHEJ) pathway and that the 
silencing cyclin D1 radiosensitizes PCa cells. 
D-type cyclins (D1, D2, and D3) are G1-specific 
cyclins that promote restriction point progression during 
G1 phase [12]. Amplification of individual cyclin D 
genes and overexpression of their encoded proteins were 
documented in a large proportion of human cancers 
[12–16]. Cyclin D1 protein expression is induced by 
growth factors in human PCa cell lines and is increased 
in a subset of PCa samples, promoting PCa cell growth 
[15, 30]. Previous studies show that silencing cyclin D1 
reduced growth in vitro and in vivo [14, 16] while its 
overexpression increased cell growth and tumorigenicity 
of androgen-dependent, androgen receptor-expressing 
LnCAP cells [31]. In the current studies, silencing cyclin 
D1 affected the tumorigenic potential of androgen-
independent PC3 and 22Rv1PCa cell lines in vitro and 
in vivo independently of the expression of androgen 
receptor. Silencing cyclin D1 in PCa cells showed a 
significant growth delay both in vitro and in vivo, with 
many cells arrested in the G1 phase of the cell cycle. 
Furthermore, cells cannot expand for more than 6 
passages. Cancer cell tumorigenicity is characterized by 
the strong ability of cancer cells to invade and migrate 
[32]. Cyclin D1 plays an important role in cell migration 
[33] promoting the migratory and invasive capacity of 
Figure 9: Cyclin D1 promotes NHJE and HR pathways responsible of DNA-DSBs repair. Schematic representation depicting 
the collaboration of cyclin D1 with the molecular pathways responsible for the DNA-DSBs repair. In dashed line, the molecular mechanism 
by which it is necessary to verify whether the action of cyclin D1 is direct or mediated by other factors. 
Oncotarget5395www.impactjournals.com/oncotarget
macrophages [34], fibroblasts [35], breast epithelial 
cells [36] and human glioblastoma cells [37–38]. The 
mechanism, rather complex, is via RhoA and binding to 
the cytoplasmic proteins Filamin A [39], Pacsin 2 [40] and 
the regulation of microRNAs such as microRNA-17/20 
[41]. Furthermore, cyclin D1 regulates metalloproteinase 
(MMPs) [42–43], traditionallyassociated with matrix 
remodeling, cancer invasion and with angiogenesis. Here, 
in characterizing the tumorigenic phenotype of cyclin D1 
silenced PCa cell lines, we showed that migration and 
invasion abilities as well as MMP2 and MMP9 activities 
were drastically reduced in the absence of cyclin D1. 
Cancer progression, invasion, and metastasis are processes 
strictly correlated with angiogenesis that plays a key role in 
PCa disease progression [44]. Herein silencing cyclin D1 
induced in vivo changes in tumor vascularity and structural 
organization, impairing the amplitude and architecture of 
the vascular bed. These effects could are in accordance 
with studies demonstrating cyclin D1depletion inhibits 
VEGF -stimulated growth of vascular endothelial cells 
causing several abnormalities to the normal organization 
of the vascular bed [45–46]. Our evidences indicated that 
cyclin D1 is essential for the maintenance of PCa cells 
tumorigenic abilities and that cyclin D1 depletion alone 
can reverts the oncogenic phenotype.
RT works through damaging the DNA of exposed 
tumor tissue leading to cell death: DNA double-strand 
breaks (DSBs), the most deleterious lesions, are repaired 
by two main pathways namely non-homologous end 
joining (NHEJ) and homologous recombination (HR).
Activation of DSBs repair genes is one of the reasons 
for chemo- and radioresistance, therefore, targeting 
DSBs repair is an attractive strategy to eliminate cancer 
[6–9]. The relationship between cyclin D1 and DSBs 
repair machinery is largely unknown and the fact that 
cyclin D1 has the hallmarks of a cellular proto-oncogene 
suggests its possible key role in promoting DNA repair 
and consequently promote radioresistance of PCa cells. 
Previous studies reported a correlation between cyclin D1 
overexpression, perturbation of the DNA repair machinery 
and acquisition of a radioresistant phenotype in cancer cells 
[17–22]. No evidences has yet collected on the relationship 
between cyclin D1 and radiosensitivity of androgen-
independent PCa cells radioresistance. Herein, silencing 
cyclin D1 radiosensitizedandrogen-independent PCa cell 
lines both in vitro, reducing cells clonogenic survival, and 
in vivo impairing xenograft growth of the PCa cells after 
RT treatment. Cancer cells escape from RT by repairing 
the DNA lesions trough the activation of highly conserved 
enzymatic pathways: only the accumulation off rank 
unrepaired breaks may generate chromosomal aberrations 
that, after a variable number of cell cycles, induce cell 
death. This mode of cell death is considered the major 
mechanism by which solid tumors respond to clinical 
radiotherapy. Apoptosis is an alternative mode of cell 
death after RT, but appears to be preferentially expressed 
in embryonal and haematopoietic cells, with significantly 
lower levels of induction in epithelial cell types as well as 
in solid human cancers with an epithelial origin [47]. Our 
data shows that the radiosensitization induced by silencing 
cyclin D1 does not depend on apoptosis but rather by 
an increased accumulation of DNA-DSBs damage; RT 
treatment did not modify the percentage of apoptotic 
cells regardless of the expression of CCDN1, while it 
drastically increased DNA-DSBs damage, as suggested by 
the accumulation of activated H2AX protein [48]. Our data 
indicate that in PCa, such as in other cancers of epithelial 
origin, RT induces cell death by promoting DNA-DSBs 
phenomena; in this scenario cyclin D1 seems to be the 
guardian against RT-induced DNA damages. HR, through 
the ATM-RAD51-and NHEJ, via the DNA-PKcs-pathway, 
are the main highly conserved enzymatic pathways 
involved in repair of RT-induced DNA-DSBs [6–10].
We finally investigated the molecular partners of cyclin 
D1 responsible of cyclin D1-mediated radioresistance in 
PCa. A proteomic screen for cyclin D1 protein partners, 
performed in several types of human tumors, shows that 
cyclin D1 interacts with proteins implicated in DNA repair 
machinery such as RAD51 [17–22]. Herein, in vitro and 
in vivo, we show that cyclin D1 silencing abrogated the 
DNA-PKcs phosphorylation/activation (NHEJ pathway) 
and RAD51 accumulation (HR pathway) induced by RT. 
Although no modifications of ATM phosphorylation/
activation status were showed, we found that cyclin 
D1physically interacts with posphorylated-activated-ATM 
as well as with activated-DNA-PKcs and RAD51: their 
associatedis increased in an RT dependent manner. Thus, 
cyclin D1 seems to play a dual role in controlling DNA-
DSBs repair pathways; firstly by regulating NHEJ and HR 
pathways by sustaining the activation of DNA-PKcs, ATM 
and the expression basal levels of RAD51 and secondly by 
directly interacting with the DNA-DSBs repair machinery. 
The key role cyclin D1 in regulating androgen independent 
PCa cells radioresistance was also demonstrated by 
the observation that silencing of DNA-PKcs or RAD51 
drastically increases the radiosensitivity of PCa cells. 
Thus, our evidence strongly suggests that cyclin D1 
regulates the activity of downstream DDR machinery 
and promotes radioresistance of androgen independent 
PCa cells. The schematic shown in Figure 9 outlines the 
mechanism identified in our findings. Many issues should 
be further investigated such as the mechanisms by which 
cyclin D1 regulates the RT-induced ATM and DNA-PKCs-
phosphorilation/activation, the mechanism by which 
cyclin D1 influences the RAD51 RT-induced DDR and 
the significance of the physical interaction between cyclin 
D1 and other members of DNA-DSBs repair machinery. 
Furthermore, cancer stem cell radioresistance has been 
described in several cancer types including prostate cancer 
[49–50] and it will be of interest to test whether silencing 
cyclin D1 in PCa cells that express stem-like properties 
improves radiosensitivity.
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In the present study, we demonstrated that cyclin 
D1 governs the tumor phenotype and participates in 
determining radioresistance of PCa cells independently by 
androgen receptor expression. Our studies suggest silencing 
cyclin D1 may improve the therapeutic effects of RT. 
MATERIALS AND METHODS
Cell culture and FACS analysis
The human prostate carcinoma cell lines 22Rv1, 
and PC3 were obtained from the American Type Culture 
Collection (Rockville, MD) and were grown in RPMI 1640 
(Life Technologies, Inc., Grand Island, NY) supplemented 
with 10% FBS. For FACS analysis cells were harvested 
by trypsin-EDTA and washed; pellets were suspended in 
0.3 ml 50% FCS in PBS, followed by addition of 0.9 ml 
70% ethanol and left O/N in the dark at 4°C prior to FACS 
analysis (Coulter Epics XL Flow Cytometer, Beckman 
Coulter CA, USA).
Viral production and infection and siRNA 
interference
Design of nucleotide sequence for cyclin D1short 
hairpin RNA (GCCACAGATGTGAAGTTCA) was 
performed with the BLOCK-iT™ RNAi Designer from 
Invitrogen. shRNA was designed that incorporated these 
sequences within a short hairpin structure, using the stem 
loop sequence 5′-TCAAGAGA-3′, which were then 
cloned between MluI and ClaI sites downstream of an H1 
promoter in the plasmid pLVTHM. Plasmid pLVTHM, 
derived from pSUPERn that contains a GFP expression 
cassette upstream of the H1 promoter, was obtained 
from Addgene. The construct was stably transduced into 
PC3 and 22Rv1 cells using a lentiviral based expression 
system [26]. 293T cells were transfected using calcium 
phosphate transfection together with the packaging 
vectors psPAX2 (virus packaging plasmid) and pMD2G 
(Addegene) (envelope plasmid; 4:3:2 ratio) by calcium–
phosphate transfection. Culture medium containing virus 
was collected 48 hours after transfection and filtrated 
through a 0.4 μm filter to remove cell debris and cells: 
viral titers were determined by measuring the percent of 
green fluorescent protein (GFP)–positive cells. Stable cell 
lines expressing shRNA were achieved by infection at 
50 multiplicity of infection (MOI). The collected viruses 
were added to the target cells in the presence of polybrene 
(2 μg/mL) and incubated for 24 hours. Four days after the 
first infection, transduced cells were isolated by FACS 
sorting for GFP + cells to > 99% purity. RNA interference 
experiments were performed with siRNA for DNA-
PKcs, ATM and RAD51 (Sancta Cruz Biotechnology) 
using Lipofectamine 2000 reagent (Invitrogen, Italy), 
according to the manufacturer’s instructions. Briefly, 
cells were plated at 40–50% confluence and transfected 
after 24 hours with 100 nM siRNA, which we ascertained 
was sufficient to detect maximum fluorescence using 
fluorescein-conjugated control siRNA.
Cell growth, soft agar colony formation, invasion 
and migration assays
Cells (20x104/well) were plated in 24-well culture 
plates. The cell number was assayed by crystal violet 
staining at 2-day intervals up to 20 days. Medium was 
changed every 4 days. Control cells were analyzed under 
the same conditions until they reached confluence. In 
order to evaluate the ability of individual cell lines to grow 
in an anchorage-independent manner, cells were plated in 
soft agar. The bottom of each well contained 2 ml of 0.5% 
agarose and RPMI 2X (Sigma Aldrich Corporation, St 
Louis, MO, USA). This compact agar was covered with 
2 ml of 0.2% agar and RPMI 2X with 5 × 103 cells. The 
medium was changed every 3 days. After 21 days, the 
wells were stained with 0.003% crystal violet, and five 
areas were randomly selected from each well in order 
to count the approximate number of colonies. The cell-
migration and invasion assays were performed using the 
CytoSelect™ ECM Cell Migration and Invasion Assay 
(8 µm, Colorimetric Format) (CELL BIOLABS, INC.) in 
accordance with manufactures instructions.
Immunoblotting
Immunoblotting was performed as previously 
described [27] using the following antibodies: anti-
cyclin D1(DCS-6), anti-ATM (H-248), anti-DNA-PKcs 
(E-6), anti-H2AX (M-20), anti-p-H2AX (3C10), anti-
RAD51 (3C10), anti-Ku86 (B-1), anti-p21waf1 (B-2), 
anti-p27Kip1 (A-10) and α-tubulin (B-7) all from Santa 
Cruz Biotechnology. Anti-pospho-Ser1981-ATM (10H11.
E12), anti-pospho-Thr2609-DNA-PKcs (10B1) were 
from abcam®. Peroxidase-conjugate anti-mouse or anti-
rabbit IgG (Amersham-Pharmacia Biotech, UK or Santa 
Cruz) were used for enhanced chemiluminescence (ECL) 
detection.
Immunoprecipitation
Cells were harvested in phosphate buffered saline, 
sedimented and lysed in 10 mM Tris pH 7, 50 mMNaCl, 
1% NP40, 1 mM ZnCl2, in addition to protease and 
phosphatase inhibitors. Protein extracts were clarified 
by centrifugation. Supernatant, normalized as equal 
amounts of proteins, were incubated with antibody anti-
cyclin D1(H-295RabbitPolyclonal) at 4°C for 3 hrs. 30 
μl of protein-G Plus (Santa Cruz Biotechnology) were 
added to collect immunocomplexes. Protein G-bound 
immunocomplexes were washed 6 times with extraction 
buffer and processed for SDS-PAGE. Immunoblotting 
was performed with anti-RAD51 (3C10) from Santa Cruz 
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Biotechnology or with anti-pospho-Ser1981-ATM (10H11.
E12), anti-pospho-Thr2609-DNA-PKcs (10B1) from 
abcam®: all the antibodies used for the immunoblotting 
were mouse monoclonal.
In vitro irradiation and colony formation assay
Radiation was delivered at room temperature 
using an x-6 MV photon linear accelerator, as previously 
described [28]. The total single dose of 4 Gy was delivered 
with a dose rate of 2 Gy/min using a source-to-surface 
distance (SSD) of 100 cm. A plate of Perspex thick 1.2 
cm was positioned below the cell culture flasks in order to 
compensate for the build-up effect. Tumor cells were then 
irradiated placing the gantry angle at 180°. Non-irradiated 
controls were handled identically to the irradiated 
cells with the exception of the radiation exposure. For 
clonogenic survival assays, exponentially growing cells in 
25-cm2 flasks were harvested by exposure to trypsin and 
counted. They were diluted serially to appropriate densities 
and plated in triplicate in 6 multi-well plates with 2 mL of 
complete medium/each well. After incubation for 24 hours, 
the cells were exposed at room temperature to radiation 
treatment as already described. The cells were then washed 
with PBS, cultured in growth medium for 14 days, fixed 
with methanol:acetic acid (10:1, v/v), and stained with 
crystal violet. Colonies containing > 50 cells were counted.
Cell viability, apoptosis, caspases- and γ-H2AX 
activation assays
A Cell Proliferation Kit I (MTT) (Sigma-Aldrich) 
was used to quantitatively measure cellular viability. 
Tunnel assay (Promega) was used to quantitatively 
measure the cellular apoptosis. Caspase-Glo®3, 8 and 
9 assays from Promega were used to measures caspase 
activity. All assays were performed accordingly to the 
manufacturer’s instructions.
Establishment of tumor xenografts and in vivo 
radiation treatment
PCa cells were grown to 80% confluence and 
harvested. Cells were re-suspended in serum free RPMI-
1640 medium with penicillin and streptomycin, mixed 
1:1 with Growth Factor Reduced (GFR) BD Matrigel 
Basement Membrane Matrix (BD Biosciences, Palo 
Alto, California). Using a cold syringe and 27-gauge 
needle, 3.5 × 106 PC3 and 5 × 10622Rv1 cells were 
injected subcutaneously into each lateral flank of male 
athymic nu/nu mice 6 weeks of age. Mice were kept under 
sterile conditions, receiving sterile nutrition and water. 
When palpable tumors (0, 5–1, 0 cm3) were established 
animals were subjected to radiation treatment. Mice were 
irradiated by two field (AP/PA) at room temperature using 
an Elekta6-MV photon linear accelerator. Five fractions 
of 2 Gy were delivered over 5 consecutive days for a total 
dose of 10 Gy with a dose rate of 1.5 Gy/min. Prior to 
irradiation, mice were anesthetized and were shielded from 
off-target radiation by a multi-leaf secondary collimator. 
Before tumor inoculation mice were randomly assigned to 
2 experimental groups, with or without radiation treatment. 
Each group was composed of 10 mice. Experiments were 
stopped 20 days after the last RT fraction and mice were 
sacrificed by carbon dioxide inhalation. Tumours were 
directly frozen in liquid nitrogen for protein analysis and 
biochemical evaluation. All the procedures involving 
animals and their care were conducted in accordance with 
the institutional guidelines. 
Evaluation of treatment response in vivo
The effects on tumour growth of different treatments 
were evaluated as follows: (1) measurement of tumour 
volume during and at the end of experiments. Tumor 
volume was assessed by measurement every 4 days with a 
Vernier calliper (length × width). The volume of the tumor 
was expressed in mm3 according to the formula 4/3π r3; 
(2) measurement of tumor weight at the end of experiment; 
(3) Time to progression (TTP), defining tumor progression 
(TP) an increase of greater than 100% of tumor volume 
with respect to baseline.
Histological and immunohistochemical analysis
Serial 3 µm sections were stained with Hematoxylin 
and Eosin (H&E) and Masson’s Trichrome in order to 
evaluate morphological aspects. For immunohistochemical 
(IHC) analysis, sections were incubated for 40 minutes in 
methanol and 3% hydrogen peroxidase solution and then 
rinsed in PBS. Samples were incubated 10 minutes in 
buffered citrate 0.01 M, pH 6, twice and rinsed in PBS. 
Sections were then treated with BSA (5%) for 10 minutes 
and finally incubated overnight with specific antibodies 
against cyclin D1 (H-295), RAD51 (H-92), Ku86 
(H-300), α-Actin (1A4) and p-ATM (10H11.E12) all from 
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, 
γH2AX (IB 100–2280) from NOVUS biologicals, used at 
dilutions of 1:100. Samples were then rinsed with PBS 
for 5 minutes and incubated with a labeled streptavidin-
biotin-peroxidase conjugate kit (Dako LSAB plus, cod.
K0675, DakoCytomation, Milan, Italy). After rinsing in 
PBS for 10 minutes the sections were incubated with 3, 
3-diaminobenzidine-tetrahydrochloride (DAB, Sigma 
Aldrich) for 1–3 minutes. The specificity of immune 
reactions was revealed by the absence of the primary 
antibodies. Lastly, the samples were counterstained 
with Mayer’s Hematoxylin and observed under a 
photomicroscope Olympus BX51 Light Microscope 
(Olympus, Optical Co. Ltd, Tokyo, Japan). Observations 
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were processed with an image analysis system (IAS, Delta 
system, Rome, Italy) and were independently performed 
by two pathologists (AV, RS) in a blinded fashion.
In vivo densitrometric quantification of proteins
Densitometric analysis for α-SMA and cyclin D1 
was obtained using “IHC Profile ImageJ” an automated 
digital program quantitates the intensity of antibody 
staining in tissue sections. The spectral deconvolution 
method of DAB/hematoxylinwas deployed, so that the 
DAB stained images could be separated and displayed 
independent of the hematoxylin image. Then the program 
selects where the marker protein is expressed the most, 
cytoplasm and/or nucleus. Therefore the deconvoluted 
image undergoes a pixel-by-pixel analysis, thus the full 
profile along with a scoring decision is provided. The 
results are shown in a four tier system which includes high 
positive, positive, low positive and negative. 
Colorimetric evaluation of collagen content
Samples (5 mm3) of tumor xenograft were removed 
and immediately immersed in 10% buffered formalin 
for paraffin embedding. Eight 15-mm thick, 100 mm2 
large sections were obtained from each liver and used for 
colorimetric evaluation. Sections for colorimetric evaluation 
were deparaffinized through successive baths in absolute 
toluene: ethanol (50:50) and 50% aqueous ethanol and water. 
Staining procedures with fast green FCF 0.1 (Chroma- 
Gesellshaft, no. IA30, Stuttgart, Germany) and Sirius Red 
F3B 0.01% (Atomergic Chemical Corporation, no. 10022; 
Plainview, NY, USA) were performed according to Gascon-
Barrè et al. [29]. Colors were eluted in 0.05 MNaOH and 
50% aqueous methanol. The eluted colors were examined 
in Lambda 4 B PE spectrophotometer. Correlation 
between absorbance and protein estimations were assessed 
according to Gascon-Barrè et al. [29]. Non-collagenous 
protein determination was obtained using the following 
formula: Non-collagenous protein (mg) = Absorbance 
at 605 nm / 2.08. Collagenous protein determination was 
obtained using the latter interference factor in the following 
formula: Collagen (μg) = (Absorbance at 540 nm) – (0.26 
absorbance at 605 nm) / 38.4 Collagen content ( collagen /
protein ratio) was calculated using the following formula: 
Collagen content (μg/mg total protein) = μg collagen / 
(μg collagen + mg non-collagenous protein) [29].
Statistical methods
Continuous variables were summarized as mean 
and standard deviation (SD) or 95% CI for the mean. For 
continuous variables, statistical comparisons between 
control and treated groups were established by carrying 
out the ANOVA Tests (a parametric one-way analysis of 
variance for independent groups). Dichotomous variables 
were summarized by absolute and/or relative frequencies. 
For Dichotomous variables, statistical comparisons 
between control and treated groups were established 
by carrying out the exact Fisher’s test. For multiple 
comparisons the level of significance was corrected by 
multiplying the P value by the number of comparisons 
performed (n) according to Bonferroni correction. TTP 
was analyzed by Kaplan-Meier curves and Gehan’s 
generalized Wilcoxon test. When more than two survival 
curves were compared the Logrank test for trend was used. 
This tests the probability that there is a trend in survival 
scores across the groups. All tests were two-sided and were 
determined by Monte Carlo significance. P values < 0.05 
were considered statistically significant. 
For TTP, fractional TTP (FTTP) for each treatment 
group was calculated as the ratio between the median 
TTP of untreated and treated tumors. This was done 
for treatment a, for treatment b and for treatment 
a + b. The expected FTV or FTTP for the << a + b >> 
combination was defined as FTVa-observed X FTVb-
observed or as FTTPa-observed X FTTP-observed. 
The ratio FTV a + b-expected/FTV a + b-observed 
or FTTP a + b-expected/FTTP a + b-observed was 
the combination Index (CI). If CI > 1, there are 
supra-additive effects and if CI < 1 infra-additive 
ones. Strictly additive effects are observed if CI = 1. 
All statistical analyses were performed using the SPSS® 
statistical analysis software package, version 10.0.
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